# Thilo Schroeder

> Thilo Schroeder is a Series B investor at Nextech Invest backing Health Care. See 21 investments, check sizes, portfolio and contact details. Updated Oct 2026.

- Type: Angel Investor
- Fund: [Nextech Invest](https://shizune.co/investors/profile/nextech-invest)
- Location: Zürich, Switzerland
- Total investments: 21
- Last investment: Sep 2026
- Lead investor: 43%
- Last updated: Oct 2026
- LinkedIn: https://www.linkedin.com/in/thilo-schroeder-7b735a23
- X (Twitter): https://x.com/schroederthilo

Thilo Schroeder is a Series B investor at Nextech Invest in Zürich focused on Health Care and Biotechnology. Thilo Schroeder is based out of Zürich, Zurich and is the Managing Partner of Nextech Invest. Thilo previously worked at Alterome Therapeutics as a Member Board Of Directors. Thilo Schroeder attended the University of Zurich.

## Contacts

5 contacts available for Thilo Schroeder: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/thilo-schroeder?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 9 | 43% |
| Biotechnology | 9 | 43% |
| Medical | 5 | 24% |
| Biopharma | 4 | 19% |
| Therapeutics | 4 | 19% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 8 | 38% |
| Series A | 3 | 14% |
| Series C | 3 | 14% |
| Series E | 3 | 14% |
| Series D | 1 | 5% |

7 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Circle Pharma | Circle Pharma is an early-stage biotechnology company applying proprietary computational design algorithms and innovative chemistry to develop cell-permeable macrocycle peptide therapeutics against important clinical targets. It does this through an iterative, rational design process that deploys large virtual libraries of conformationally diversemacrocycle scaffolds selected for inherent permeability. The company was founded by Matt Jacobson and Scott Lokey in 2012 and is headed by David J. Earp. | $92.5M | Series E | Sep 16, 2026 | http://circlepharma.com |
| Stipple Bio | Stipple Bio is a biotech company that focuses on advancing cellular profiling and target discovery using epitope-level resolution technologies. It develops proprietary platforms that analyze cellular interactions, enabling researchers to identify precise therapeutic targets for drug development. The company’s approach is particularly applied inoncology, where it aims to discover tumor-specific cell surface epitopes to create safer and more effective treatments. Its “Pointillist” platform is designed to map these epitopes with high precision, helping overcome limitations of traditional therapies such as off-target toxicity. | $100M | Series A | Apr 06, 2026 | https://www.stipple.bio |
| Atavistik Bio | Atavistik Bio is a biotechnology company that specializes in the discovery and development of precision allosteric small molecules aimed at treating metabolic diseases and cancer. The company aims to revolutionize therapeutic approaches by focusing on selective allosteric therapeutics, which can potentially transform treatment options for seriousdiseases. | $40M | Series B | Mar 05, 2026 | https://atavistikbio.com/ |
| Parabilis Medicines | Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach. | $305M | Series F | Jan 08, 2026 | https://parabilismed.com |
| Atavistik Bio | Atavistik Bio is a biotechnology company that specializes in the discovery and development of precision allosteric small molecules aimed at treating metabolic diseases and cancer. The company aims to revolutionize therapeutic approaches by focusing on selective allosteric therapeutics, which can potentially transform treatment options for seriousdiseases. | $120M | Series B | Dec 18, 2025 | https://atavistikbio.com/ |
| Circle Pharma | Circle Pharma is an early-stage biotechnology company applying proprietary computational design algorithms and innovative chemistry to develop cell-permeable macrocycle peptide therapeutics against important clinical targets. It does this through an iterative, rational design process that deploys large virtual libraries of conformationally diversemacrocycle scaffolds selected for inherent permeability. The company was founded by Matt Jacobson and Scott Lokey in 2012 and is headed by David J. Earp. | $90M | Series D | Sep 03, 2024 | http://circlepharma.com |
| Alterome Therapeutics | Alterome Therapeutics is a precision oncology biotech developing alteration-specific therapeutics to address high value and validated oncogenic drivers. | $132M | Series B | Apr 03, 2024 | https://www.alterome.com |
| FogPharma | FogPharma was born from the scientific and entrepreneurial vision of founder Greg Verdine, a pioneer in the discovery and development of new drug classes that “drug the undruggable.” FogPharma’s cell-penetrating miniproteins (CPMPs) are a broad new class of medicines that can drug targets beyond the reach of conventional therapeutics. Together withworld-leading experts and collaborators in cancer biology and therapy, our team is building a drug discovery powerhouse having passion, knowledge, and creativity to develop fundamentally new cancer treatments.FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma’s network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer.We are laser-focused and unstoppable in our mission to deliver the new class of medicines to patients and their families to bring them years to life and life to years. | $145M | Series E | Mar 01, 2024 | http://www.fogpharma.com |
| Parabilis Medicines | Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach. | $145M | Series E | Mar 01, 2024 | https://parabilismed.com |
| Atavistik Bio | Atavistik Bio is a biotechnology company that specializes in the discovery and development of precision allosteric small molecules aimed at treating metabolic diseases and cancer. The company aims to revolutionize therapeutic approaches by focusing on selective allosteric therapeutics, which can potentially transform treatment options for seriousdiseases. | $40M | Venture - Series Unknown | Dec 19, 2023 | https://atavistikbio.com/ |

10 of 21 investments shown.

## Co-investors
- [The Column Group](https://shizune.co/investors/profile/the-column-group) — VC Fund, 18 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 7 deals together
- [Boxer Capital](https://shizune.co/investors/profile/boxer-capital) — VC Fund, 5 deals together
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 5 deals together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/biotechnology-value-fund) — VC Fund, 4 deals together
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 4 deals together

## About Nextech Invest

VC Fund · Zürich, Switzerland

Nextech Invest is a venture capital and private equity firm specializing in early, mid-stage, late-stage, and emerging growth investments. The firm also invests in incorporation, spin-outs, reverse-take-over, and PIPE transactions. It only considers investments where evidence in preclinical animal models that a drug is efficacious is available or a device prototype fulfills the requirements. The firm seeks to invest in the field of information technology, biotechnology, and healthcare with a focus on oncology companies developing cancer drugs and diagnostics. It prefers to invest in life science and enabling technologies with a focus on interdisciplinary technical and scientific projects, therapies, diagnostics, medical technologies, and services. The firm seeks to invest in companies based in Africa, the Middle East, Asia, North America, and Europe including Switzerland, Germany, and neighboring regions. It also considers co-investments in the rest of Europe. The firm seeks to invest between CHF 1 million ($0.93 million) and CHF 5 million ($4.7 million) per financing round. It seeks a Board position in the portfolio companies. The firm seeks to exit its investments within three years via trade sale.

5 contacts available at Nextech Invest.

| Name | Title | Profile |
| --- | --- | --- |
| Kanishka Pothula | Partner | https://shizune.co/investors/profile/kanishka-pothula |
| Megan Graziano | Director Of Operations | https://shizune.co/investors/profile/megan-graziano |
| Melissa McCracken | Partner | https://shizune.co/investors/profile/melissa-mccracken |
| Thilo Schroeder | Managing Partner | https://shizune.co/investors/profile/thilo-schroeder |
| Thomas Geninatti | Principal | — |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Thilo Schroeder invest in?

Thilo Schroeder invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series A stage. Most of the 21 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Thilo Schroeder?

Public channels for Thilo Schroeder include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Thilo Schroeder last invest?

The most recent investment recorded for Thilo Schroeder closed in Sep 2026. Shizune tracks 21 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co